Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 5/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812286 | 0.74 | SCN9A (0.37) | SCN5ASCN9ACTSDCYP2D6MCL1 | |
| SCHEMBL4814117 | 0.64 | NPC1 (0.35) | — | |
| SCHEMBL4811289 | 0.62 | SCN9A (0.38) | SCN5ASCN9ACTSDCYP2D6BACE1 | |
| SCHEMBL6567682 | 0.60 | SCN5A (0.43) | SCN5ASCN9ABACE1 | |
| SCHEMBL4817379 | 0.60 | LMNA (0.40) | CTSDCYP2D6BACE1 | |
| SCHEMBL10431135 | 0.57 | MCL1 (0.57) | SCN9ACYP2D6MCL1 | |
| SCHEMBL3139954 | 0.57 | F2 (0.42) | — | |
| SCHEMBL10934425 | 0.57 | MCL1 (0.51) | SCN9ACYP2D6MCL1 | |
| SCHEMBL11192421 | 0.56 | KMT2A (0.53) | SCN9ACYP2D6 | |
| SCHEMBL10988016 | 0.55 | MEN1 (0.49) | SCN9AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354943-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2008-04-08 | — | — | US | claimed |
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-28 | — | — | US | claimed |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | claimed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | claimed |
| US-7358264-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-7354943-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2008-04-08 | — | — | US | disclosed |
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-28 | — | — | US | disclosed |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | disclosed |
| US-6864290-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN, LLP (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1404328-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | disclosed |
| WO-2003006021-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | SCN5A 1457/4885SCN9A 2355/4885PADI4 3793/4885 |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | SCN5A 1457/4885SCN9A 2355/4885PADI4 3793/4885 |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | SCN5A 1443/4885SCN9A 2386/4885PADI4 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.